Jane Street Group LLC Has $14.75 Million Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Jane Street Group LLC reduced its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 40.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 132,422 shares of the specialty pharmaceutical company’s stock after selling 89,469 shares during the quarter. Jane Street Group LLC owned approximately 0.22% of Jazz Pharmaceuticals worth $14,753,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of JAZZ. EverSource Wealth Advisors LLC boosted its position in Jazz Pharmaceuticals by 55.1% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 273 shares of the specialty pharmaceutical company’s stock valued at $30,000 after buying an additional 97 shares during the last quarter. GAMMA Investing LLC boosted its position in Jazz Pharmaceuticals by 41.3% in the 3rd quarter. GAMMA Investing LLC now owns 414 shares of the specialty pharmaceutical company’s stock valued at $46,000 after buying an additional 121 shares during the last quarter. Arizona State Retirement System boosted its position in Jazz Pharmaceuticals by 0.8% in the 2nd quarter. Arizona State Retirement System now owns 16,580 shares of the specialty pharmaceutical company’s stock valued at $1,770,000 after buying an additional 130 shares during the last quarter. Itau Unibanco Holding S.A. boosted its position in Jazz Pharmaceuticals by 63.2% in the 3rd quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock valued at $49,000 after buying an additional 172 shares during the last quarter. Finally, Waterfront Wealth Inc. boosted its position in Jazz Pharmaceuticals by 2.5% in the 2nd quarter. Waterfront Wealth Inc. now owns 9,411 shares of the specialty pharmaceutical company’s stock valued at $1,004,000 after buying an additional 230 shares during the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,700 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the sale, the executive vice president now owns 33,048 shares of the company’s stock, valued at $4,078,453.68. This trade represents a 10.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the sale, the chief executive officer now directly owns 428,976 shares in the company, valued at $47,547,699.84. This represents a 0.23 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 6,753 shares of company stock valued at $816,289. 4.20% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. Robert W. Baird increased their price objective on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an “outperform” rating in a research report on Monday, November 18th. JPMorgan Chase & Co. increased their price objective on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the company an “overweight” rating in a research report on Monday, August 19th. Needham & Company LLC reissued a “buy” rating and issued a $207.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, November 21st. Cantor Fitzgerald reissued an “overweight” rating and issued a $140.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday, September 9th. Finally, Piper Sandler reissued an “overweight” rating and issued a $163.00 price target (down previously from $166.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, November 21st. Three research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $175.33.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock opened at $120.15 on Wednesday. The company has a market capitalization of $7.26 billion, a PE ratio of 16.92, a PEG ratio of 1.04 and a beta of 0.57. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $134.17. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The stock’s fifty day simple moving average is $116.59 and its 200 day simple moving average is $111.85.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.